Table of Contents
Executive Summary — 6
SWOT
Analysis — 7
Hungary Pharmaceuticals And Healthcare
Industry SWOT — 7
Hungary Political
SWOT — 8
Hungary Economic SWOT — 9
Hungary Business Environment SWOT — 10
Pharmaceuticals &
Healthcare Business Environment — 11
Table: Emerging
Europe Pharmaceutical Business Environment Rankings for
Q409 — 11
Limits to Potential
Returns — 12
Risks to Realisation of
Returns — 12
Hungary – Market
Summary — 13
Regulatory Regime — 14
Recent EU Regulatory Developments — 15
Intellectual
Property Regime — 16
Pricing
Regime — 17
Table: Hungary – Pharmaceutical Price
Build-Up — 18
Table: Hungary – Average Pharmacy
Mark-Up — 19
Price Cuts — 19
Reimbursement Regime — 20
Pricing and Reimbursement
Reforms — 21
Industry
Developments — 23
Epidemiology — 23
Healthcare Financing — 23
Health
Insurance — 24
Healthcare Reforms — 25
Hospital Sector Reforms — 26
Pharmaceutical
Industry — 27
Recent Company
Activities — 28
Wholesale and Retail Pharmacy
Sector — 30
Research and Development
(R&D) — 31
Table: Special Incentive Package For Investors
Willing To Establish An R&D Facility Worth At Least EUR10mn in
Hungary — 32
Recent R&D Sector
Developments — 33
Biotechnology
Sector — 34
Medical Devices — 35
Industry Forecast Scenario — 37
Overall Market
Forecast — 37
Table: Hungary - Drug Market Indicators,
Historical Data and Forecasts — 38
Key Growth Factors
– Industry — 39
Table: Hungary - Health Expenditure
Indicators, Historical Data and Forecasts — 40
Key Growth
Factors – Macroeconomic — 41
Table: Hungary -
Economic Activity, 2006-2013 — 44
Prescription Market
Forecast — 45
Table: Hungary - Prescription Market
Indicators, Historical Data and Forecasts (US$mn unless otherwise)
stated) — 46
Patented Market
Forecast — 47
Table: Hungary - Patented Drug Market
Indicators, Historical Data and Forecasts — 47
Generics
Market Forecast — 48
Table: Hungary - Generics Market
Indicators, Historical Data and Forecasts — 49
OTC Market
Forecast — 50
Table: Hungary – OTC Market
Indicators, Historical Data and Forecasts (HUFmn unless otherwise)
stated) — 51
Medical Devices
Forecast — 52
Table: Hungary – Medical Device Market
Indicators, Historical Data and Forecasts (US$mn) — 52
Pharmaceutical Trade Forecasts — 53
Table: Hungary –
Pharmaceutical Trade Indicators, Historical Data and Forecasts
(US$mn) — 54
Other Healthcare Data
Forecasts — 54
Table: Hungary – Other Healthcare
Indicators, Historical Data and Forecasts — 54
Key Risks
to BMI’s Forecast Scenario — 55
Competitive
Landscape — 56
Table: Leading Pharmaceutical Companies By
Ownership — 56
Company Monitor — 57
Multinational Companies — 57
Pfizer — 57
Novartis — 59
Sanofi-Aventis — 60
GlaxoSmithKline — 62
Merck & Co — 63
Eli Lilly — 65
Teva — 67
Domestic
Manufacturers — 69
Gedeon Richter — 69
Egis Pharmaceuticals (Servier) — 73
Country Snapshot:
Hungary Demographic Data — 76
Section 1:
Population — 76
Table: Demographic Indicators,
2005-2030 — 76
Table: Rural/Urban Breakdown,
2005-2030 — 77
Section 2: Education and
Healthcare — 77
Table: Education,
2002-2005 — 77
Table: Vital Statistics,
2005-2030 — 77
Section 3: Labour Market and Spending
Power — 78
Table: Employment Indicators,
2001-2006 — 78
Table: Consumer Expenditure, 2000-2012
(US$) — 79
Table: Average Annual Wages,
2000-2012 — 79
BMI Methodology — 80
How We Generate Our Pharmaceutical Industry Forecasts — 80
Pharmaceutical Business Environment Ratings
Methodology — 81
Ratings Overview — 81
Table: Pharmaceutical Business Environment Indicators — 82
Weighting — 83
Table: Weighting Of
Components — 83
Sources — 83
| 
View Cart
